Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors
作者:Yan Shi、Jing Zhang、Mengxiao Shi、Stephen P. O’Connor、Sharon N. Bisaha、Chi Li、Doree Sitkoff、Andrew T. Pudzianowski、Saeho Chong、Herbert E. Klei、Kevin Kish、Joseph Yanchunas、Eddie C.-K. Liu、Karen S. Hartl、Steve M. Seiler、Thomas E. Steinbacher、William A. Schumacher、Karnail S. Atwal、Philip D. Stein
DOI:10.1016/j.bmcl.2009.06.014
日期:2009.8
of the thiourea and ketene aminal functional groups. We report the design and synthesis of a novel class of cyanoguanidine-based lactam derivatives as potent and orally active FXa inhibitors. The SAR studies led to the discovery of compound 4 (BMS-269223, Ki = 6.5 nM, EC2xPT = 32 μM) as a selective, orally bioavailable FXa inhibitor with an excellent in vitro liability profile, favorable pharmacokinetics
的Ñ,Ñ '二取代的氰基胍是在硫脲和乙烯酮缩醛胺官能团的生物电子等排优良。我们报告了新型的氰基胍基内酰胺衍生物作为有效和口服活性FXa抑制剂的设计和合成。SAR研究导致发现化合物4(BMS-269223,K i = 6.5 nM,EC 2xPT = 32μM)作为一种选择性的,口服可生物利用的FXa抑制剂,在动物模型中具有出色的体外反应性,良好的药代动力学和药效学。介绍了FXa中4结合的X射线晶体结构,并讨论了关键的配体-蛋白质相互作用。